OBJECTIVES: The present study was aimed to explore the prognostic strength of Sox2 and Oct4A in hepatocellular carcinoma (HCC). DESIGN AND METHODS: We investigated the expression of Sox2 and Oct4A in five hepatoma cell lines, one immortalized normal liver cell line, HCC tissues with matched nontumorous liver tissues and normal liver tissues by reverse transcription-polymerase chain reaction. RESULTS: Sox2 and Oct4A mRNA were overexpressed in hepatoma cell lines and tumor tissues. Sox2 or Oct4A positive expression was significantly associated with an aggressive phenotype. Both univariate and multivariate analyses revealed that Sox2 or Oct4A was an independent prognostic factor for HCC. When using subgroup analysis, the patients with a co-expression of Sox2/Oct4A had the poorest prognosis. Further analysis demonstrated that Sox2 alone or Sox2/Oct4A could stratify outcome in HCC patients with early stage. CONCLUSIONS: Sox2 and Oct4A can be novel predictors of poor prognosis for patients undergoing resection of HCC.
OBJECTIVES: The present study was aimed to explore the prognostic strength of Sox2 and Oct4A in hepatocellular carcinoma (HCC). DESIGN AND METHODS: We investigated the expression of Sox2 and Oct4A in five hepatoma cell lines, one immortalized normal liver cell line, HCC tissues with matched nontumorous liver tissues and normal liver tissues by reverse transcription-polymerase chain reaction. RESULTS:Sox2 and Oct4A mRNA were overexpressed in hepatoma cell lines and tumor tissues. Sox2 or Oct4A positive expression was significantly associated with an aggressive phenotype. Both univariate and multivariate analyses revealed that Sox2 or Oct4A was an independent prognostic factor for HCC. When using subgroup analysis, the patients with a co-expression of Sox2/Oct4A had the poorest prognosis. Further analysis demonstrated that Sox2 alone or Sox2/Oct4A could stratify outcome in HCC patients with early stage. CONCLUSIONS:Sox2 and Oct4A can be novel predictors of poor prognosis for patients undergoing resection of HCC.
Authors: Ivan V Litvinov; Elena Netchiporouk; Brendan Cordeiro; Hanieh Zargham; Kevin Pehr; Martin Gilbert; Youwen Zhou; Linda Moreau; Anders Woetmann; Niels Ødum; Thomas S Kupper; Denis Sasseville Journal: Oncoimmunology Date: 2014-12-21 Impact factor: 8.110
Authors: Hideo Watanabe; Qiuping Ma; Shouyong Peng; Guillaume Adelmant; Danielle Swain; Wenyu Song; Cameron Fox; Joshua M Francis; Chandra Sekhar Pedamallu; David S DeLuca; Angela N Brooks; Su Wang; Jianwen Que; Anil K Rustgi; Kwok-kin Wong; Keith L Ligon; X Shirley Liu; Jarrod A Marto; Matthew Meyerson; Adam J Bass Journal: J Clin Invest Date: 2014-03-03 Impact factor: 14.808